⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312656 | 0.50 | — | — | |
| SCHEMBL5223367 | 0.50 | — | — | |
| SCHEMBL7520513 | 0.50 | — | — | |
| SCHEMBL4249416 | 0.50 | — | — | |
| SCHEMBL3932336 | 0.50 | — | — | |
| SCHEMBL15869348 | 0.47 | — | — | |
| Methylamine SCHEMBL1330940 | 0.47 | — | — | |
| SCHEMBL10417889 | 0.47 | — | — | |
| Methylamine SCHEMBL6988408 | 0.47 | — | — | |
| Methylamine SCHEMBL1331336 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287156-B1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2275413-B1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-8263590-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20110201606-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-7964592-B2 | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-1606265-B1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-02-02 | — | — | EP | disclosed |
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| CN-101006079-A | Pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-25 | — | — | CN | disclosed |
| EP-1789044-A1 | PHENYLAMINOPYRIDINES | Basilea Pharmaceutica AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| CN-1832929-A | 2, 4-pyrimidinediamines for the treatment of neoplastic diseases, inflammatory diseases and immune system disorders | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | disclosed |
| WO-2006027348-A1 | PHENYLAMINOPYRIDINES | BASILEA PHARMACEUTICA AG (CH) | 2006-03-16 | — | — | WO | disclosed |